Rajendra Badwe, MD, Tata Memorial Hospital, Mumbai, India, discusses a multi-center randomized trial to test the impact of peri-tumoral infiltration of local anesthesia (LA) before surgery on survival in women with early breast cancer. The primary endpoint was disease-free survival (DFS) and the secondary endpoint was overall-survival (OS). The study included 1600 patients randomized to LA or no LA. At 72 months, there were 109 DFS in the LA arm and 146 in the no-LA arm. At 6-years DFS rates were 86.1% and 81.7% in LA and No-LA arms, respectively and OS was 89.9% and 86.2%, respectively. The trial demonstrated peri-tumoral injection of lidocaine before surgery can reduce 1 of 4 recurrences and 3 of 10 deaths in women with early breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.